OphRx Overview
- Founded
-
2014
- Status
-
Private
- Latest Deal Type
-
Joint Venture
- Latest Deal Amount
-
$1M
- Investors
-
4
OphRx General Information
Description
Developer of a non-invasive drug delivery technology designed to treat diseases of the eye. The company's technology uses lyotropic liquid crystals, a non-invasive alternative to current delivery modalities, enabling healthcare providers to treat diseases at the front and the back of the eye, such as intravitreal injections.
Contact Information
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Primary Office
- Kiryat Atidim Building 7
- 2nd Floor
- Tel Aviv 6158101
- Israel
+972 000-000-0000
OphRx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Joint Venture | 01-Jan-2014 | $1M | Completed | Pre-Clinical Trials |
OphRx Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Robert David | Chief Medical Officer |
OphRx Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| BioLight Life Sciences | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Integra Holdings | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Kremer and Lieberman Groups | Other | Minority | 000 0000 | 000000 0 | |
| XL-Vision Sciences | Corporation | Minority | 000 0000 | 000000 0 |